Replies to post #111673 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Yes - had read it but have you seen it

http://www.medpagetoday.com/meetingcoverage/aaic/52740

This is in the same boat as AXON.

In any case they had 18 months data on some 399 patients and not 32. They have enrolled 800 patients now



"Those analyses, conducted in different ways, showed that the active-drug group did show significantly less decline in cognitive performance. There was a mean 3.1-point difference between groups in Mini-Mental State Examination scores at month 18 (P=0.008).

In contrast, though, the post-stoppage analyses -- which included an intent-to-treat analysis, four sensitivity analyses using different imputation methods for the missing data, an analysis of all the actual data from all treated patients, and a subgroup analysis of patients with mild symptoms -- all pointed toward a small but real benefit. "Every single one of them was positive," Sabbagh said (Patients' cognitive function did continue to decline with azeliragon, but at a slower rate than the placebo group -- ending with a 3-point difference in ADAS-Cog score at 18 months)."